Iradimed Corporation (NASDAQ:IRMD) Stake Boosted by BNP Paribas Financial Markets

BNP Paribas Financial Markets grew its stake in shares of Iradimed Corporation (NASDAQ:IRMD) by 39.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,661 shares of the medical equipment provider’s stock after acquiring an additional 5,863 shares during the period. BNP Paribas Financial Markets’ holdings in Iradimed were worth $1,039,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Copeland Capital Management LLC grew its holdings in shares of Iradimed by 0.3% during the 3rd quarter. Copeland Capital Management LLC now owns 422,425 shares of the medical equipment provider’s stock valued at $21,244,000 after acquiring an additional 1,433 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Iradimed by 1.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 218,924 shares of the medical equipment provider’s stock valued at $9,620,000 after acquiring an additional 2,079 shares in the last quarter. Isthmus Partners LLC grew its holdings in shares of Iradimed by 1.1% during the 2nd quarter. Isthmus Partners LLC now owns 72,664 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 759 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Iradimed by 189.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 66,632 shares of the medical equipment provider’s stock valued at $3,351,000 after acquiring an additional 43,635 shares in the last quarter. Finally, Liontrust Investment Partners LLP bought a new stake in Iradimed in the second quarter worth $2,830,000. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

Iradimed Trading Up 1.1 %

Shares of NASDAQ:IRMD opened at $55.30 on Wednesday. The stock has a market capitalization of $700.65 million, a PE ratio of 37.88 and a beta of 0.82. Iradimed Corporation has a 1 year low of $40.18 and a 1 year high of $57.95. The firm has a fifty day moving average price of $52.30 and a 200 day moving average price of $47.76.

Iradimed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Friday, November 15th were issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 1.08%. The ex-dividend date was Friday, November 15th. Iradimed’s dividend payout ratio is presently 41.10%.

Insider Buying and Selling

In related news, CFO John Glenn sold 2,500 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total value of $135,450.00. Following the completion of the sale, the chief financial officer now directly owns 4,383 shares in the company, valued at approximately $237,470.94. This represents a 36.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 37.10% of the stock is currently owned by corporate insiders.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.